SCHEMBL2864239

SCHEMBL2864239

O=S(=O)(NC(Cc1ccccc1)C1CCCCC1)c1ccc(F)cc1F

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.46
DPP4 P27487 7/20 0.44
DPP7 Q9UHL4 5/20 0.44
KCNH2 Q12809 4/20 0.44
CYP3A4 P08684 1/20 0.43
CYP2C19 P33261 1/20 0.43
ADRB3 P13945 1/20 0.43
TAAR1 Q96RJ0 2/20 0.42
DPP9 Q86TI2 4/20 0.40
DPP8 Q6V1X1 3/20 0.40
KMT2A Q03164 1/20 0.40
GAA P10253 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
PTPN1 P18031 1/20 0.40
POLB P06746 1/20 0.39
ALDH1A1 P00352 1/20 0.39
SIGMAR1 Q99720 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2867346 0.77 ADRB3 (0.40) CYP3A4CYP2C19ADRB3POLB
SCHEMBL2857888 0.76 PSMB5 (0.52) ALDH1A1
SCHEMBL2853532 0.74 ALDH1A1 (0.58) CYP3A4CYP2C19KMT2AGAAHTT
SCHEMBL7870961 0.73 NPY5R (0.38) USP30DPP4DPP7KCNH2ADRB3
SCHEMBL27145035 0.73 NR3C1 (0.39) USP30ADRB3GAAHTTNPSR1
SCHEMBL27145036 0.73 NR3C1 (0.39) USP30ADRB3GAAHTTNPSR1
SCHEMBL30807603 0.73 NR3C1 (0.39) USP30ADRB3GAAHTTNPSR1
SCHEMBL13412195 0.72 POLB (0.50) DPP4DPP7KCNH2KMT2ANPSR1
SCHEMBL2857264 0.72 PYGL (0.46) KMT2APOLB
SCHEMBL2875665 0.69 EPHX2 (0.53) CYP3A4CYP2C19KMT2AHTTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2253328-A1 Cycloalkyl inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-11-24 EP disclosed
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNN3, KCNQ5 USP30 835/4885DPP4 2095/4885DPP7 1216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.